JP2016540740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540740A5 JP2016540740A5 JP2016527396A JP2016527396A JP2016540740A5 JP 2016540740 A5 JP2016540740 A5 JP 2016540740A5 JP 2016527396 A JP2016527396 A JP 2016527396A JP 2016527396 A JP2016527396 A JP 2016527396A JP 2016540740 A5 JP2016540740 A5 JP 2016540740A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- cre
- camk2a
- group
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 230000003612 virological Effects 0.000 claims description 2
- 230000003278 mimic Effects 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- 230000005014 ectopic expression Effects 0.000 description 3
- 101700083887 MAPK1 Proteins 0.000 description 2
- 102100016823 MAPK1 Human genes 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 description 1
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 1
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010018659 Grand mal convulsion Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N Kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 101710027479 MAP2K1 Proteins 0.000 description 1
- 102100006473 MAP2K1 Human genes 0.000 description 1
- 101700028785 MEK1 Proteins 0.000 description 1
- 101700053443 MKK1 Proteins 0.000 description 1
- 101700052154 MPK1 Proteins 0.000 description 1
- 210000001577 Neostriatum Anatomy 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N Oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N Picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- GHWJEDJMOVUXEC-UHFFFAOYSA-N SKF-81,297 Chemical compound C1NCCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 GHWJEDJMOVUXEC-UHFFFAOYSA-N 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 101700009925 WNK1 Proteins 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 101710024775 erkB Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Description
一実施形態では、薬剤がmiR−128である、またはmiR−128と90%以上の配列相同性を有する薬剤である。特定の実施形態では、miR−128を増加させるおよび/または活性化することができる薬剤が、化学的に安定化されたmiR−128、miR−128模倣物、miR−128をコードする核酸およびmiR−128をコードするウイルスベクターからなる群から選択される。一実施形態では、miR−128を増加させるおよび/または活性化することができる薬剤が、脳由来神経栄養因子である。
図3は、miR−128欠損によって引き起こされた異常な運動活動が、薬理学的ERK阻害または異所性miR−128発現によって修正されることを示す。
(A)Drg1a−cre;miR−128−2fl/flおよび同腹子対照マウスに、ビヒクルまたは12mg/kgのMEK1阻害剤SL327のいずれかを腹腔内注射した(n=5/群)。薬物注射30分後のERK2リン酸化のウエスタンブロット解析(左)およびビヒクルまたはSL327注射後の運動活動(右)を示す。二元配置分散分析、引き続いてボンフェローニポストテスト。エラーバーは、平均値の標準誤差、*p≦0.05、**p≦0.01、***p≦0.001を示す。
(B)miR−128の過剰発現が、ドーパミン枯渇線条体においてD1−ニューロン反応性亢進を抑制する。片側性6−OHDA損傷Camk2a−cre;Rosa−miR−128または対照マウス(n=11/群)におけるベースラインでのおよびコカイン(10mg/kg)またはD1−アゴニストSKF81297(5mg/kg)に反応した反対側回転の数を示す。エラーバーは平均値の標準誤差、ウェルチのt検定、**p≦0.01を示す。
(C)miR−128がマウスの化学的誘発発作に対する感受性を低下させる。痙攣誘発薬(pro−convulsive drug)カイニン酸(30mg/kg、p値=0.005)またはピクロトキシン(3mg/kg、p値=0.04)の腹腔内注射60分後に強直間代発作を示すCamk2a−cre;Rosa−miR−128または同腹子対照マウス(n=12/群)の数を示す。p値はフィッシャーの正確確率検定によって計算した。
(A)Drg1a−cre;miR−128−2fl/flおよび同腹子対照マウスに、ビヒクルまたは12mg/kgのMEK1阻害剤SL327のいずれかを腹腔内注射した(n=5/群)。薬物注射30分後のERK2リン酸化のウエスタンブロット解析(左)およびビヒクルまたはSL327注射後の運動活動(右)を示す。二元配置分散分析、引き続いてボンフェローニポストテスト。エラーバーは、平均値の標準誤差、*p≦0.05、**p≦0.01、***p≦0.001を示す。
(B)miR−128の過剰発現が、ドーパミン枯渇線条体においてD1−ニューロン反応性亢進を抑制する。片側性6−OHDA損傷Camk2a−cre;Rosa−miR−128または対照マウス(n=11/群)におけるベースラインでのおよびコカイン(10mg/kg)またはD1−アゴニストSKF81297(5mg/kg)に反応した反対側回転の数を示す。エラーバーは平均値の標準誤差、ウェルチのt検定、**p≦0.01を示す。
(C)miR−128がマウスの化学的誘発発作に対する感受性を低下させる。痙攣誘発薬(pro−convulsive drug)カイニン酸(30mg/kg、p値=0.005)またはピクロトキシン(3mg/kg、p値=0.04)の腹腔内注射60分後に強直間代発作を示すCamk2a−cre;Rosa−miR−128または同腹子対照マウス(n=12/群)の数を示す。p値はフィッシャーの正確確率検定によって計算した。
図11は、異所性発現miR−128による致死的てんかんおよび活動亢進の用量依存的救済を示す。miR−128の異所性発現は、用量依存的様式で、Camk2a−cre;miR−128−2fl/flマウスの自発運動亢進を正常化し、死亡を防ぐ。(左側パネル)異所性発現miR−128の1つ(淡青色)または2つ(濃青色)の対立遺伝子の不在(黒色)または存在下でのCamk2a−cre;miR−128−2fl/flマウスの寿命を示す。(右側パネル)Camk2a−cre;miR−128−2fl/fl;Rosa−miR−128(青色)、Camk2a−cre;miR−128−2fl/fl(黒色)および野生型マウス(白色)の運動活動を示す。
Claims (1)
- miR−128の発現または活性を増加させることができる前記薬剤が、化学的に安定化されたmiR−128、miR−128模倣物、miR−128をコードする核酸およびmiR−128をコードするウイルスベクターからなる群から選択される、請求項14に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361896463P | 2013-10-28 | 2013-10-28 | |
US61/896,463 | 2013-10-28 | ||
US201361898952P | 2013-11-01 | 2013-11-01 | |
US61/898,952 | 2013-11-01 | ||
PCT/US2014/062664 WO2015066034A1 (en) | 2013-10-28 | 2014-10-28 | Compositions and methods for modulating neuronal excitability and motor behavior |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020079949A Division JP7014852B2 (ja) | 2013-10-28 | 2020-04-30 | 神経興奮性および運動行動を調節するための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016540740A JP2016540740A (ja) | 2016-12-28 |
JP2016540740A5 true JP2016540740A5 (ja) | 2018-01-11 |
JP6700180B2 JP6700180B2 (ja) | 2020-05-27 |
Family
ID=53005028
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016527396A Active JP6700180B2 (ja) | 2013-10-28 | 2014-10-28 | 神経興奮性および運動行動を調節するための組成物および方法 |
JP2020079949A Active JP7014852B2 (ja) | 2013-10-28 | 2020-04-30 | 神経興奮性および運動行動を調節するための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020079949A Active JP7014852B2 (ja) | 2013-10-28 | 2020-04-30 | 神経興奮性および運動行動を調節するための組成物および方法 |
Country Status (8)
Country | Link |
---|---|
US (3) | US10087443B2 (ja) |
EP (2) | EP3825402A1 (ja) |
JP (2) | JP6700180B2 (ja) |
AU (2) | AU2014342535B2 (ja) |
CA (1) | CA2929098A1 (ja) |
ES (1) | ES2836133T3 (ja) |
PL (1) | PL3074050T3 (ja) |
WO (1) | WO2015066034A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101814868B1 (ko) * | 2015-06-18 | 2018-01-04 | 재단법인대구경북과학기술원 | 마이크로 rna와 nmda 수용체의 상관관계를 이용한 해마의 기능감소 판단 방법, 기능감소 억제 방법 및 기능감소 억제제 스크리닝 방법 |
JP6923509B2 (ja) * | 2015-07-28 | 2021-08-18 | オトノミ—,インク. | 切断型のtrkbおよびtrkcのアンタゴニストを使用する処置 |
CA3001594A1 (en) | 2015-10-14 | 2017-04-20 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
CN110290794A (zh) * | 2016-11-01 | 2019-09-27 | 纽约州州立大学研究基金会 | 5-卤代尿嘧啶修饰的微rna及其在癌症治疗中的用途 |
WO2019227255A1 (zh) * | 2018-05-26 | 2019-12-05 | 深圳市博奥康生物科技有限公司 | miRNA-128过表达载体的构建及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830857A (en) * | 1995-07-14 | 1998-11-03 | Amgen Inc. | Method of treating epilepsy |
BR9712824A (pt) * | 1996-09-13 | 1999-12-21 | Advanced Medicine Research Ins | Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico |
WO2006070292A2 (en) * | 2004-10-12 | 2006-07-06 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
CA2850323A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
AU2009271524A1 (en) * | 2008-07-16 | 2010-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of GM98 (MRF) in remyelination |
CA2808372C (en) * | 2010-08-16 | 2021-11-16 | Brainstem Biotec Ltd. | Methods of generating oligodendrocytes and cell populations comprising same |
WO2012097261A2 (en) | 2011-01-14 | 2012-07-19 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
EP2761002B1 (en) | 2011-09-28 | 2021-11-17 | Royal College of Surgeons in Ireland | Inhibition of microrna-134 for the treatment of seizure-related disorders and neurologic injuries |
JP5850702B2 (ja) * | 2011-10-25 | 2016-02-03 | 国立大学法人岐阜大学 | 間葉系細胞の分化調節剤およびこれを用いた医薬、並びに間葉系細胞への分化調節作用を有する物質のスクリーニング方法 |
GB201223244D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Gmbh | Micrornas as therapeutics and biomarkers for epilepsy |
US9434945B2 (en) | 2013-08-02 | 2016-09-06 | University Of Maryland, Baltimore | Use of miR-23a-3p and/or miR-27a-3p mimics as therapeutic agents for inhibition of neuronal apoptosis following brain injury |
CN103656685B (zh) | 2014-01-10 | 2016-01-13 | 厦门大学 | microRNA-219在制备抗癫痫药物中的应用 |
WO2015175965A1 (en) | 2014-05-15 | 2015-11-19 | The Research Foundation For Suny | Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof |
-
2014
- 2014-10-28 WO PCT/US2014/062664 patent/WO2015066034A1/en active Application Filing
- 2014-10-28 AU AU2014342535A patent/AU2014342535B2/en active Active
- 2014-10-28 PL PL14857152T patent/PL3074050T3/pl unknown
- 2014-10-28 ES ES14857152T patent/ES2836133T3/es active Active
- 2014-10-28 US US15/032,255 patent/US10087443B2/en active Active
- 2014-10-28 EP EP20194773.6A patent/EP3825402A1/en active Pending
- 2014-10-28 EP EP14857152.4A patent/EP3074050B1/en active Active
- 2014-10-28 JP JP2016527396A patent/JP6700180B2/ja active Active
- 2014-10-28 CA CA2929098A patent/CA2929098A1/en active Pending
-
2018
- 2018-10-01 US US16/148,015 patent/US10870853B2/en active Active
-
2020
- 2020-04-30 JP JP2020079949A patent/JP7014852B2/ja active Active
- 2020-07-01 AU AU2020204419A patent/AU2020204419B2/en active Active
- 2020-11-16 US US17/099,209 patent/US20210317451A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016540740A5 (ja) | ||
Klein et al. | Identification of modifier genes in a mouse model of Gaucher disease | |
Cooper et al. | Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease | |
Lunnon et al. | Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies | |
Sturm et al. | The Piwi‐pi RNA pathway: road to immortality | |
WO2015081101A8 (en) | Adeno-associated virus vectors for treatment of glycogen storage disease | |
Popadin et al. | Genetic and epigenetic regulation of human lincRNA gene expression | |
Guffanti et al. | Transposable elements and psychiatric disorders | |
Lemmers et al. | SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
WO2016049163A3 (en) | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder | |
WO2016081923A3 (en) | METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs | |
BR112016018598A2 (pt) | vetor de vírus adeno-associados | |
JP2017514496A5 (ja) | ||
WO2012018387A3 (en) | Compositions and methods for discovery of causative mutations in genetic disorders | |
EA201690759A1 (ru) | Генетические маркеры, позволяющие прогнозировать ответ на ацетат глатирамера | |
BR112012016808A2 (pt) | cepa hospedeira bacteriana expressando dsbc recombinante e tendo atividade tsp reduzida | |
Wang et al. | Abnormal global alternative RNA splicing in COVID-19 patients | |
Abe et al. | Association of genetic variants with dyslipidemia | |
Lin et al. | Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment? | |
Li et al. | Evolutionary and ontogenetic changes in RNA editing in human, chimpanzee, and macaque brains | |
Rogozin | Complexity of gene expression evolution after duplication: protein dosage rebalancing | |
Peedicayil et al. | Some implications of an epigenetic-based omnigenic model of psychiatric disorders | |
郭睿 et al. | Transcriptome analysis of Ascosphaera apis stressing larval gut of Apis cerana cerana | |
Tan et al. | Significant differences in incubation times in sheep infected with bovine spongiform encephalopathy result from variation at codon 141 in the PRNP gene |